Brief: Akari Therapeutics Announces $12.75 Million Registered Direct Offering
12/09/2022 13:38
Sept 12 (Reuters) - Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS ANNOUNCES $12.75 MILLION REGISTERED
DIRECT
OFFERING
* AKARI THERAPEUTICS - ENTERED INTO DEFINITIVE AGREEMENTS
FOR
PURCHASE AND SALE OF 15 MILLION AKARI ADSS AT A PURCHASE PRICE
OF $0.85 PER ADS
Source text for Eikon: ID:nGNX5Cx47C
Further company coverage: AKTX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics